Purple Innovation, Inc. stockholders approved a reverse stock split of Class A and Class B common stock at a ratio between 1-for-10 and 1-for-30, as determined by the Board of Directors. Additionally, the Board and CEO Robert T. DeMartini entered into an amendment to his employment agreement, granting him eligibility for an incremental $1,000,000 cash bonus with a multi-stage vesting-schedule. Purple Innovation, Inc. develops and manufactures high-performance medical device components for the healthcare industry.
